New venture capitalist will bring completely new service model to biotechnology and health technology growth companies
It is clear that there is a lack of angel investor capital in the biotech industry. Besides investments, early-stage biotech companies also need guidance in risk management, building up long-term strategies, budgeting, setting up operational functions, legal support, setting up early-stage sales and marketing functions, and commercialization.
“Almaral is not your average venture capital company. We create value for our clients by answering the strategic and operational questions that a startup company can face in its early stages. Our team has excellent business knowledge and a solid understanding of the biotechnology industry. We have money, but we also know how to use it wisely. We have a unique network of partners and advisors to support our clients in their operational functions and to expand internationally,” says CEO Dr Maria Severina.
The investor team has exceptionally strong evidence of success
Almaral's investment partners have strong evidence of success in the internationally attractive biotech industry. In just a couple of decades, CEO Maria Severina managed to build HyTest into an international success story. Developing antibodies and antigens, the company grew from a two-person startup to one of Finland's most profitable companies. A year ago, HyTest was sold to Chinese Minday for hundreds of millions of euros. Chairman of the Board of Almaral
Alex Michine has been promoting future technologies for the global bioeconomy and has been an active spokesperson for the potential of cross-disciplinary collaboration. He has founded and successfully ran three biotech/cleantech SMEs, including since 2008, MetGen, which won the Frost and Sullivan European Industrial Enzymes Technology Innovation Award.
“We have been highly successful in our business. I believe the main reason for our success has been that we have focused on what we do best and have had the courage to trust good partners in many business support services. In addition to financing, we now want to offer this same model to our own customers,” says Severina.
Contact information:
Email: info@almaral.eu
For interviews: Maria Severina, +358405540127
Keywords
About Hansdotter Oy
Almaral invests in early-stage biotechnology and life sciences startups. Along with investments Almaral offers guidance in risk management, building up long term strategies, budgeting, setting up operational functions, legal support, setting up early-stage sales and marketing functions, and commercialization.
www.almaral.eu
Subscribe to releases from Hansdotter Oy
Subscribe to all the latest releases from Hansdotter Oy by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Hansdotter Oy
Mainostoimisto Hansdotterin toimitusjohtajaksi digiosaaja Tatu Koivu3.6.2024 10:11:39 EEST | Tiedote
Koko kuusivuotisen taipaleensa tasaisesta ja kannattavasti kasvanut mainostoimisto Hansdotter vaihtaa toimitusjohtajaa. Uudeksi toimitusjohtajaksi 1.6. alkaen on nimitetty yrityksen menestyksekkäästä digiloikasta vastannut operatiivinen johtaja Tatu Koivu. Hän näkee päätehtävänään asiakkaista ja ihmisistä välittämisen.
Mainostoimisto Hansdotterin oma suljettu tekoäly opetetaan asiakkaiden tavoille29.2.2024 09:00:00 EET | Tiedote
Suljettu tekoäly mahdollistaa sen turvallisen käytön myös luovan markkinointiviestinnän apuna. Hansdotterin omaa tekoälyä ja sen mahdollisuuksia yhdessä työntekijöiden kanssa kehittää yrityksen tekoälyasiantuntija Eeva Rauramo.
The Planet Company ja Hansdotter tuovat yhdessä yritysten vastuullisuustyöhön mitattavuutta ja vaikuttavuutta11.10.2023 11:50:49 EEST | Tiedote
The Planet Companyn ainutlaatuinen toimintamalli auttaa yrityksiä tekemään vastuullisuuspuheista mitattavia tekoja sekä saamaan riippumattoman vastuullisuusasiantuntijan arvion teoilleen. Markkinointiviestintätoimisto Hansdotter taas auttaa kertomaan vastuullisuusteoista vaikuttavasti sekä sisäisille että ulkoisille kohderyhmille.
Almaralilta merkittävä sijoitus syöpädiagnostiikkaa kehittävälle Genomillille5.9.2023 09:55:53 EEST | Tiedote
Almaral on tehnyt huomattavan pääomasijoituksen syöpädiagnostiikan edelläkävijänä tunnetulle Genomillille. Sijoitus on Almaralilta rohkea ja ennakkoluuloton investointi tarkkuusdiagnostiikan tulevaisuuteen.
A rare new type of ecosystem for startup growth architecture and funding is born in Finland26.4.2023 15:03:46 EEST | Press release
Finland has long been one of the most interesting markets for startup investors. However, an organization focused on helping founders develop and grow their startups has been missing from the market. Almaral and Liquido have now teamed up to create a unique combination of insight and knowledge in startup growth architecture and funding.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom